Redeye sees the FDA's fast track designation for EVX-01 as a validation of the personalised vaccin a...
Redeye comments on Isofol’s board proposing a liquidation of the company after considering different...
Redeye comments on CLS’ announcement that the company repays SEK3m of its loan with a directed share...
Targets SEK 2bn in revenue and adj. EBITA margin 6% in 2023 Targets 10% org.
Redeye lowers its valuation of Irlab following yesterday’s phase IIb top-line data with Mesdopetam i...
Q4 report due 21 February We forecast sales of SEK 190m, adj.
Redeye provides a research update following Xavi Solutions’ updated financial targets.
Redeye updates its estimates ahead of the Q4 report (due 22 February) with slight downward adjustmen...
IRLAB Therapeutics has announced top-line data from its Phase IIb trial investigating mesdopetam as ...
Redeye leaves its view on Idogen following the outcome of its rights issue.
Trots stark försäljning var Q3 ett svalt kvartal utan nya ordar.
EcoRub tillkännagav den 17 januari att bolaget startat ett samarbete med Svensk Däckåtervinning för ...
IRLAB fails primary endpoint in PD-LIDs Positive secondary endpoint keeps the door open Conference c...
NoHo Partners has been selected as the main supplier for restaurant services by Helsinki Expo and Co...
Looks set to reach midpoints of FY'22 guidance Expect intensifying Last Mile volume decline from pap...
M&A-driven EMS company with a solid track record '23e-'25e adj.
Infracom är en komplett leverantör av digitala telefoni-, IT-, och nätverkstjänster.
Redeye comments on Smart Wires latest press release stating the Company was awarded a contract worth...
Redeye provides an update on Adverty following its Q3 2022 report.
